Drugs / E-602
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05259696 | Feb 2022 → Oct 2024 | breast cancer, colon carcinoma, gastric cancer, gastroesophageal cancer +7 | Palleon Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E-602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05259696 ↗ |
| Modality | Protein / enzyme biologic | “Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)” NCT05259696 ↗ |
| Route | Intravenous | “administered weekly, via IV infusion” NCT05259696 ↗ |